B. Riley reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Friday morning. The brokerage currently has a $205.00 target price on the biopharmaceutical company’s stock.
Several other research analysts have also recently weighed in on ALNY. Sanford C. Bernstein reaffirmed a buy rating and issued a $135.00 price target (up previously from $94.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 21st. Ladenburg Thalmann Financial Services reaffirmed a buy rating and issued a $146.00 price target (up previously from $90.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 21st. BMO Capital Markets reaffirmed an outperform rating and issued a $134.00 price target (up previously from $99.00) on shares of Alnylam Pharmaceuticals in a report on Friday, September 22nd. Chardan Capital reaffirmed a buy rating and issued a $124.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, September 25th. Finally, Jefferies Group upped their target price on shares of Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a buy rating in a research report on Tuesday, September 26th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of Buy and an average price target of $121.20.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $131.00 on Friday. The firm has a market cap of $12,880.00, a price-to-earnings ratio of -24.95 and a beta of 2.98. Alnylam Pharmaceuticals has a 1-year low of $35.98 and a 1-year high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.21) EPS. research analysts expect that Alnylam Pharmaceuticals will post -5.29 EPS for the current year.
In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the completion of the sale, the executive vice president now directly owns 45,201 shares in the company, valued at $5,490,113.46. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the sale, the senior vice president now owns 17,749 shares of the company’s stock, valued at $2,151,178.80. The disclosure for this sale can be found here. Insiders sold 274,075 shares of company stock valued at $35,356,089 over the last quarter. 4.30% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. FMR LLC boosted its position in Alnylam Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after buying an additional 815,270 shares during the period. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 13.4% during the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after buying an additional 759,295 shares during the period. Janus Henderson Group PLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $53,226,000. Orbimed Advisors LLC boosted its position in Alnylam Pharmaceuticals by 69.7% during the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock valued at $127,453,000 after buying an additional 445,600 shares during the period. Finally, BlackRock Inc. boosted its position in Alnylam Pharmaceuticals by 9.3% during the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after buying an additional 441,957 shares during the period. Institutional investors and hedge funds own 88.41% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.